Status:
UNKNOWN
Association Between Gait Assessed by Intelligent System and Cognitive Function in Silent Cerebrovascular Disease
Lead Sponsor:
Shanghai Zhongshan Hospital
Collaborating Sponsors:
The Affiliated Hospital Of Guizhou Medical University
Fudan University
Conditions:
Silent Stroke
Eligibility:
All Genders
60-85 years
Brief Summary
This study is a multi-center prospective cohort study. We will continuously recruit subjects with silent cerebrovascular disease aged 60 to 85 years from Shanghai and Guizhou. Data including demograph...
Detailed Description
The neurological function of all subjects was assessed based on the following tests under the guidance of a physician. The timed up-and-go test was used to evaluate the subjects' gait function, requir...
Eligibility Criteria
Inclusion
- Aged between 60 and 85 years.
- Diagnosed with silent cerebrovascular disease/silent stroke, which is consistent with the 2016 statement issued by the American Heart Association (AHA) and American Stroke Association (ASA):
- No previous clear history of stroke and no clinical symptoms or mild clinical symptoms that fail to attract clinical attention;
- Cranial MRI showing at least one of the following within 5 years: lacunar infarct of vascular origin; white matter hyperintensity of vascular origin; cerebral microbleeds;
- Consciousness and ability to complete cognitive assessment
- Ability to stand and walk independently and complete gait assessment without assistance from others.
- Ability to sign the informed consent.
Exclusion
- Intracranial lesions that have been clearly diagnosed as demyelination disease, white matter dystrophy, intracranial space-occupying lesions, or autoimmune encephalitis.
- Gait disorder that has been diagnosed as Parkinson's disease, normal cranial hydrocephalus, an otogenic disease, subacute combined degeneration, peripheral neuropathy, osteoarthritis, or lumbar disease.
- Cognitive disorders that have been diagnosed, such as Alzheimer's disease, frontotemporal dementia, Lewy body dementia, etc.
- Severe neurological diseases such as previous cerebral trauma, epilepsy, and myelopathy, etc.
- Severe cardiovascular complications and intolerance to the assessment
- Severe visual or hearing impairment, aphasia, cognitive disorder, gait disorder, etc., that results in the inability to cooperate for cognitive and gait assessment
- Refusal to participate in the study
- Other anomalies that could not be included in the exclusion criteria, but are considered inappropriate to be included in this study.
Key Trial Info
Start Date :
July 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
1600 Patients enrolled
Trial Details
Trial ID
NCT04456348
Start Date
July 1 2020
End Date
December 31 2021
Last Update
July 2 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.